Hydroxychloroquine and COVID-19 - A narrative review. - OpacWWW

Szczegóły
Abstrakt

Tytuł:: Hydroxychloroquine and COVID-19 - A narrative review.
Autorzy:: Bajpai J; Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India.
Pradhan A; Department of Cardiology, King George's Medical University, Lucknow, 226003, India.
Singh A; Department of Medicine, King George's Medical University, Lucknow, 226003, India.
Kant S; Department of Respiratory Medicine, King George's Medical University, Lucknow, 226003, India. Electronic address: .
Źródło:: The Indian journal of tuberculosis [Indian J Tuberc] 2020 Dec; Vol. 67 (4S), pp. S147-S154. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: Jan. 2015- : New Delhi : Elsevier
Original Publication: New Delhi, Tuberculosis Assn. of India.
MeSH Terms:: SARS-CoV-2*
COVID-19 Drug Treatment*
Enzyme Inhibitors/*pharmacology
Hydroxychloroquine/*pharmacology
Enzyme Inhibitors/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use
References:: Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188. (PMID: 32164085)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. (PMID: 23716032)
Biosci Trends. 2020 Mar 16;14(1):72-73. (PMID: 32074550)
Travel Med Infect Dis. 2020 Mar - Apr;34:101663. (PMID: 32289548)
JAMA Netw Open. 2020 Apr 24;3(4):e208857. (PMID: 32330277)
N Engl J Med. 1988 Jan 7;318(1):1-6. (PMID: 3336379)
N Engl J Med. 2020 Jun 18;382(25):2411-2418. (PMID: 32379955)
EBioMedicine. 2017 Oct;24:189-194. (PMID: 29033372)
Nat Med. 2020 Jun;26(6):808-809. (PMID: 32488217)
Int J Antimicrob Agents. 2020 Jul;56(1):105949. (PMID: 32205204)
Arch Dermatol. 1980 May;116(5):587-91. (PMID: 6990871)
Intensive Care Med. 2020 May;46(5):854-887. (PMID: 32222812)
Indian J Crit Care Med. 2020 Jan;24(Suppl 1):S6-S30. (PMID: 32205954)
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. (PMID: 32391667)
Clin Pharmacokinet. 1996 Oct;31(4):257-74. (PMID: 8896943)
Clin Infect Dis. 2020 Jul 28;71(15):732-739. (PMID: 32150618)
JAMA Cardiol. 2020 Sep 01;5(9):1036-1041. (PMID: 32936252)
BMJ. 2020 May 14;369:m1844. (PMID: 32409486)
Nat Rev Rheumatol. 2020 Mar;16(3):155-166. (PMID: 32034323)
Cell Res. 2013 Feb;23(2):300-2. (PMID: 23208422)
Cell Discov. 2020 Mar 18;6:16. (PMID: 32194981)
J Clin Rheumatol. 2013 Aug;19(5):286-8. (PMID: 23872551)
JAMA. 2020 Jun 23;323(24):2493-2502. (PMID: 32392282)
Travel Med Infect Dis. 2020 May - Jun;35:101738. (PMID: 32387409)
Med Mal Infect. 2020 Jun;50(4):384. (PMID: 32240719)
Int J Antimicrob Agents. 2020 Apr;55(4):105945. (PMID: 32194152)
J Infect. 2020 Jun;80(6):607-613. (PMID: 32283152)
JAMA. 2020 May 12;323(18):1824-1836. (PMID: 32282022)
JAMA Intern Med. 2020 May 1;180(5):698-706. (PMID: 32119028)
N Engl J Med. 2013 May 2;368(18):1665-8. (PMID: 23635046)
Contributed Indexing:: Keywords: COVID-19; Hydroxychloroquine; Immunomodulator; Pandemic; QT prolongation
Substance Nomenclature:: 0 (Enzyme Inhibitors)
4QWG6N8QKH (Hydroxychloroquine)
Entry Date(s):: Date Created: 20201214 Date Completed: 20201224 Latest Revision: 20230328
Update Code:: 20240104
PubMed Central ID:: PMC7836863
DOI:: 10.1016/j.ijtb.2020.06.004
PMID:: 33308661
: Czasopismo naukowe

COVID 19 infection is unarguably the worst pandemic of this century. Till date there is no promising drug and vaccine available to treat this deadly viral infection. In the early phase chloroquine phosphate and hydroxychloroquine sulphate have been used to fight this illness on the basis of handful observational and small randomized and small-randomized studies. The paucity of clinical evidences of an unequivocal beneficial effect of chloroquine and hydroxychloroquine on COVID-19 has resulted in the passionate use of the drug for moderate to severe cases only and stimulated the need for large clinical trials for this and other molecules. In this review, we describe in brief the mechanism of action, the clinical studies, factors for cardiac toxicity, guidelines and future directions for hydroxychloroquine use in management of COVID-19 infection.
Competing Interests: Conflicts of interest The authors have none to declare.
(Copyright © 2020. Published by Elsevier B.V.)

Informacja

Hydroxychloroquine and COVID-19 - A narrative review.